Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AXT Inc (AXTI) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

AXT Inc vs Citius Pharmaceuticals Inc — how do they compare? AXT Inc trades at $78.1 (market cap $4.83B), while Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M). The key difference: AXT Inc is far larger — about 241.4× Citius Pharmaceuticals Inc's market cap, and AXT Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

AXTICTXR
Market Cap
$4.83B$20.01M
Sector
TechnologyHealth
52-Week High
$140.83$1.82
52-Week Low
$2.05$0.48
Enterprise Value
$4.50B$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AXT Inc

AXTI is trading at $76.84, up 4.11% with strong bullish momentum following better-than-expected Q2 2026 earnings. The stock shows bullish technical signals with support at $72 and resistance at $77. Recent financials indicate a turnaround with Q2 EPS of $0.19 beating estimates and revenue growth driven by record indium phosphide demand for AI data centers.

The outlook appears positive with strong AI-driven demand and capacity expansion plans, though valuation metrics remain elevated with P/S of 30.53. Key risks include execution challenges in meeting demand and competitive pressures in the semiconductor substrate market. Analyst consensus is strongly bullish with 73% buy ratings and $72.50 price target.

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AXT Inc

AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.

Read more on AXTI

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR